OncoMatch/Clinical Trials/NCT06921837
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
Is NCT06921837 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BDC-4182 for gastric cancer adenocarcinoma metastatic.
Treatment: BDC-4182 — A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: CLDN18 expression ≥ 1% of tumor cells IHC ≥ 2+ or Positive (≥ 1% of tumor cells IHC ≥ 2+ or Positive)
If prior Claudin 18 IHC expression is known, the subject must have some degree of Claudin 18 expression as defined as Positive or have expression ≥ 1% of tumor cells IHC ≥ 2+
Disease stage
Required: Stage STAGE 4, STAGE 3
metastatic (Stage 4) or unresectable (Stage 3)
Prior therapy
Must have received: locally available standard therapies
must have received at least 1-2 prior lines of locally available standard therapies or must be intolerant of standard therapies
Cannot have received: any investigational agent or standard anti-cancer therapies
Any investigational agent or standard anti-cancer therapies within 28 days before starting study treatment or within 5 estimated elimination half-lives, whichever is shorter
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify